Condition: Advanced Or Metastatic Merkel Cell Carcinoma · Sponsor: TuHURA Biosciences, Inc.
This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.
This description comes directly from the study's public registry record.
James Bianco, MD · 8138756600 · jbianco@tuhurabio.com
Always discuss trial participation with your own doctor first.
| H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | Recruiting |
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06940440